<DOC>
	<DOCNO>NCT00000902</DOCNO>
	<brief_summary>The purpose study determine value change anti-HIV medication child progressive HIV disease receive previous treatment . Plasma viral load ( level HIV blood ) probably effectively reduce give patient anti-HIV drug affect virus various stage development . Changing medication may enhance result treatment .</brief_summary>
	<brief_title>A Study Management Combination Anti-HIV Drug Therapy HIV-Positive Children With Prior Treatment</brief_title>
	<detailed_description>The Master RAD Protocol base concept optimal suppression viral load vivo achieve patient rapidly progress advanced HIV disease ( RAD ) use antiretroviral combination inhibit viral replication distinct sit action . Antiretroviral combination choose hypothesis simultaneous change many new agent possible necessary maximally reduce plasma viral load . In open-label , multicenter study patient randomize 1 4 group base prior antiretroviral experience . Each regimen consist 4 drug include combination nucleoside reverse transcriptase inhibitor ( stavudine , lamivudine , zidovudine , didanosine , zalcitabine ) plus nevirapine ( NVP ) , nelfinavir ( NFV ) , ritonavir ( RTV ) . Patients must naive least 2 4 drug regimen least 1 novel drug must NVP , NFV , RTV . Prior randomization NFV- RTV-containing regimen , patient stratify HIV RNA ( great equal 50,000 less 50,000 ) must able receive 2 novel drug .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Your child may eligible study : Is HIVpositive . Is ages 6 month 21 year ( consent parent guardian require 18 ) . Has HIV blood level 50,000 copies/mL 2 consecutive occasion , take antiHIV therapy . Has advance HIV disease disease progression receive 8 week continuous unchanged antiHIV therapy . Is able receive least one following : RTV , NVP , NFV . Exclusion Criteria Your child eligible study : Is receive treatment serious bacterial , viral , opportunistic ( HIVassociated ) infection within 14 day prior study entry . Has history pancreatitis peripheral neuropathy . Has cancer require chemotherapy . Is allergic study medication . Is take certain medication . Is pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>